Aim: To analyze responses to first-line metastatic renal cell carcinoma (mRCC) treatment stratified by risk criteria. Patients & methods: Clinical trials and observational studies of patients aged ≥18 years, published January 2005-May 2019, were identified via Ovid from MEDLINE, EMBASE, the Cochrane Central Trials Register and the Cochrane Database of Systematic Reviews. Data extracted included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Results: 47/1269 articles met eligibility criteria. Most studies stratified patients by International Metastatic RCC Database Consortium (n = 19) or Memorial Sloan Kettering Cancer Center (n = 21). PFS, OS and ORR varied according to risk group. Conclusion: Pembrolizumab + axitinib, ipilimumab + nivolumab and avelumab + axitinib were most effective across all risk groups. Favorable-risk patients benefit from sunitinib treatment.
Future oncology (London, England). 2020 Sep 01 [Epub ahead of print]
Shouki Bazarbashi, Abdullah Alsharm, Faisal Azam, Hazem El Ashry, Jamal Zekri
Department of Medical Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Faculty of Medicine, Alfaisal University, Riyadh 12713, Saudi Arabia., Department of Medical Oncology, King Fahad Medical City, Riyadh, 12231, Saudi Arabia., Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, 32253, Saudi Arabia., Department of Medical Affairs, Pfizer Ltd, Jeddah, 21391, Saudi Arabia., Department of Medical Oncology, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.